One-size-fits-all intravenous delivery of biologics may be giving way to alternate delivery routes that enable safer and more efficient drug administration. Michael Eisenstein reports.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Evaluating the administration costs of biologic drugs: development of a cost algorithm
Health Economics Review Open Access 23 October 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cortelezzi, A. et al. Leukemia 23, 2027–2033 (2009).
Stilgenbauer, S. et al. J. Clin. Oncol. 27, 3994–4001 (2009).
Li, G. et al. Int. J. Pharm. 368, 109–115 (2009).
Ottiger, M. et al. Invest. Ophthalmol. Vis. Sci. 50, 779–786 (2009).
Author information
Authors and Affiliations
Supplementary information
Supplementary Text and Figures
Supplementary Table (XLS 22 kb)
Rights and permissions
About this article
Cite this article
Eisenstein, M. Something new under the skin. Nat Biotechnol 29, 107–109 (2011). https://doi.org/10.1038/nbt.1768
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.1768
This article is cited by
-
Evaluating the administration costs of biologic drugs: development of a cost algorithm
Health Economics Review (2014)
-
Intranasal delivery to the brain
Nature Biotechnology (2011)